Answers are grounded in this paper and cite their sources.
Bipolar Disorder (BD) is a chronic mental illness characterized by alternating manic-depressive episodes, with 0.53% as its global lifetime prevalence. Clinical treatment needs to follow the principle of long-term management based on medications. During the manic episodes of bipolar disorder patients, both first-generation antipsychotics (e.g., chlorpromazine and haloperidol) and second-generation antipsychotics (e.g., olanzapine, clozapine, quetiapine, and risperidone) can provide effective therapeutic outcomes. However, these medications may also negatively impact physiological indicators such as blood glucose, blood lipid, and blood pressure through mechanisms like drug-induced neuroregulation, insulin resistance, and mitochondrial damage. This metabolic disorder may increase the risk of developing chronic diseases such as coronary heart disease and type 2 diabetes. This review focuses on the metabolic disorders caused by the use of second-generation antipsychotics alone or in combination with mood stabilizers (lithium salts/valproate). It systematically evaluates the intervention efficacy of hypoglycemic/lipid-regulating drugs and integrates traditional Chinese medicine-assisted treatment regimens. The research results provide multi-dimensional management strategies for the clinical prevention and treatment of antipsychotic-related metabolic abnormalities.
No takes yet. Share an insight, caveat, or question.
Xinwei Li (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: